4Q21 Mavyret sales were $427M, flat QoQ: https://news.abbvie.com/news/press-releases/abbvie-reports-full-year-and-fourth-quarter-2021-financial-results.htm The $427M consisted of: $197M US; $230M ex-US. HCV new-patient starts, particularly in the US, are not (yet) back to pre-pandemic levels. Full-year 2021 Mavyret sales were $1.71B.